Fig. 4: Engineered transfer vector architectures partially rescue LVV infectivity. | Gene Therapy

Fig. 4: Engineered transfer vector architectures partially rescue LVV infectivity.

From: Enzymatically amplified linear dbDNATM as a rapid and scalable solution to industrial lentiviral vector manufacturing

Fig. 4: Engineered transfer vector architectures partially rescue LVV infectivity.The alternative text for this image may have been generated using AI.

A Infectious (TU/mL) and (B) genome-containing particle (GP/mL) titres of LVV produced using 1 μg/mL plasmid (mass 2:1:1:1) or 0.5 μg/mL dbDNA (molar 4:3:3:4) and the indicated transfer vectors. C Infectious titre of LVV produced with as described in panel (A) using LV-eGFP-pA-RS1 and LV-RS1- eGFP-pA-RS1 transfer vectors. D Infectious titre of LVV produced using 0.7 μg/mL dbDNA and the indicated molar construct ratios. Error bars represent the standard deviation between replicates.

Back to article page